Showing results (11-20 of 59) with videos related to

Sort By:
Pageof 6
Journal of Sleep Research|September 17, 2016
EEG spectral analysis of NREM sleep in a large sample of patients with insomnia and good sleepers: effects of age, sex and part of the nightVladimir Svetnik, Ellen S Snyder, Junshui Ma, et al.
Headache|November 9, 2010
Antimigraine efficacy of telcagepant based on patient's historical triptan responseTony W Ho, Jes Olesen, David W Dodick, et al.
Sleep Medicine|May 21, 2016
Effects of suvorexant on sleep architecture and power spectral profile in patients with insomnia: analysis of pooled phase 3 dataEllen Snyder, Junshui Ma, Vladimir Svetnik, et al.
Human Psychopharmacology|October 21, 2014
Addition of an NK1 receptor antagonist to an SSRI did not enhance the antidepressant effects of SSRI monotherapy: results from a randomized clinical trial in patients with major depressive disorderWilliam A Ball, Duane B Snavely, Richard J Hargreaves, et al.
Journal of Clinical Psychopharmacology|June 28, 2021
Effects of Bedtime Dosing With Suvorexant and Zolpidem on Balance and Psychomotor Performance in Healthy Elderly Participants During the Night and in the MorningHubert Bland, Xiaodong Li, Eric Mangin, et al.
Sleep|November 8, 2017
Insight Into Reduction of Wakefulness by Suvorexant in Patients With Insomnia: Analysis of Wake BoutsVladimir Svetnik, Ellen S Snyder, Peining Tao, et al.
Sleep Medicine|December 8, 2018
Effects of suvorexant on the Insomnia Severity Index in patients with insomnia: analysis of pooled phase 3 dataW Joseph Herring, Kathryn M Connor, Ellen Snyder, et al.
Cephalalgia : an International Journal of Headache|August 10, 2014
Randomized controlled trial of the orexin receptor antagonist filorexant for migraine prophylaxisAlmira Chabi, Ying Zhang, Saheeda Jackson, et al.
Schizophrenia Research|March 26, 2013
Randomized crossover study of the histamine H3 inverse agonist MK-0249 for the treatment of cognitive impairment in patients with schizophreniaMichael F Egan, Xin Zhao, Regina Gottwald, et al.
Clinical Neuropharmacology|October 24, 2017
A Phase Ib Randomized Controlled Study to Evaluate the Effectiveness of a Single-Dose of the NR2B Selective N-Methyl-D-Aspartate Antagonist MK-0657 on Levodopa-Induced Dyskinesias and Motor Symptoms in Patients With Parkinson DiseaseW Joseph Herring, Christopher Assaid, Kerry Budd, et al.
Pageof 6